Möchten Sie immer auf dem neuesten Stand bleiben?

New York, USA, April 23, 2026 (GLOBE NEWSWIRE) -- Global Perfusion Systems Market to Register Incremental Growth at a CAGR of ~5% by 2034 | DelveInsight The global perfusion systems market is...

New York, USA, April 23, 2026 (GLOBE NEWSWIRE) -- Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight The...

New York, USA, April 22, 2026 (GLOBE NEWSWIRE) -- Global Respiratory Care Devices Market to Grow at a Substantial Growth Rate of ~8% by 2034 | DelveInsight The respiratory care devices market is...

Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a...

Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of...

EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune...

Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive...

Lehi, Utah, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, January 27, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system...

Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief...